Maria Ornella Nicoletto, MD

Maria Ornella Nicoletto, MD
LIST of publications with IF
Total IF: 336.422
(2011 Journal of Citation Report Institute of Scientific Information)
Journal
American Journal Clinical Oncology
Anticancer Res
Breast Cancer Research and treatment
Cancer
Cancer Chemother Pharmacol
Cancer Letters
Cancer Treat Reports
Cancer Treat. Rev
Clinical Chemistry Laboratory Medicine
Crit. Rev. Oncol./Hematol.
European Journal of Cancer
European Journal Cancer care(Engl)
Eur. J. Gynaecol. Oncol.
Gynecol. Oncol.
JAMA
Journal Oncology Pharmacy Practice
Int. J. Gynecol. Cancer
Int J Med Sci
Journal of Clinical Oncology
J Chemother
Journal Medical genetics
Lancet
Mol Cancer Therapeutics
Oncology (Basel)
Oncology Report
Tumor Biology
Tumori
Anticancer Drugs
Total IF
IF
2.005
1.725
4.469
4.771
2.833
4.238
13.757
6.054
2.15
4.411
5.536
1.17
0.474
3.888
30
0
1.646
2.065
18.372
0,825
6.305
39.06
10.143
2.267
2.297
2.518
0.606
2.232
Publications #
5
4
1
1
4
1
1
1
1
2
3
1
1
2
1
3
2
1
3
1
1
3
1
1
1
1
6
1
54
Total IF
10.025
6.9
4.469
4.771
11.332
4.238
13.757
6.054
2.15
8.822
16.61
1.17
0.474
7.776
30
0
3.29
2.065
55.116
0,825
6.305
117.18
10.143
2.267
2.297
2.518
3.636
2.232
336.422
Elenco pubblicazioni
1988-2013
1. Ferrazzi E., Pappagallo L., Nicoletto 0., et Al. Phase Il Evaluation of
4'Epi-Doxorubicin in Patients with Metastatic Colorectal Carcinoma. Tumori, 70:
297-300, 1984.
2. Paccagnella A., Tredese F., Salvagno L., Brandes A., Chiarion Sileni V., Daniele
0.,Fornasiero A., Fosser V., Nicoletto 0., Maggino T. and Fiorentino M.V.
Peptichemio in pretreated patients with ovarian cancer. Cancer Treatment Reports
Vol. 69, n. 1, 17-20 January 1985
3. Fiorentino MV, Nicoletto 0., De Besí P., Stefani G., Tredese F., Vínante 0.,
Fornasiero A., Cecchetto A., Maggino T. , Marchesoni D., Nardelli G., Onnis A.
Localized ovarian cancer: surgery plus chemotherapy. Eur. J. Cancer Clin. Oncol.
22, 11: 1365-1370, 1986.
4. Nicoletto MO, Fiorentino MV, Vinante O, Prosperi A, Tredese F, Tumolo S, Cima
GP, Monfardini S. Experience with Intraperitoneal Alpha-2a Interferon. Oncology.
1992;49(6):467-73.
5. Nicoletto MO, Padrini R, Ferrazzi E, Nascimben O, Visona E, Tumolo S, Palumbo
M, Costa L, Vinante O, Monfardini S, et al. Phase I-II intraperitoneal mitoxantrone
in advanced pretreated ovarian cancer. Eur J Cancer. 1993;29A(9):1242-8..
6. M.0. Nicoletto, R. Padrini, H. Koussis, A. Rosabian, S. Aversa, L. Endrizzi, P.
Azzoni, M. Palumbo, M.V. Fiorentino.Continuous mitoxantrone infusion in
pretreated epithelial ovarian cancer Cancer Chemother Pharmacol 1995, 35:
506-510.
7. Nicoletto M.O., S. Tumulo, R. Talamini, L. Salvagno, S. Franceschi, E. Visona', G.
Marin, F. Angelini, G. Brigato, C. Scarabelli, A. Carbone, A. Cecchetto, A.
Prosperi, A. Rosabian, M. Giusto, G. Cima, S. Morassut, 0. Nascimben, 0.
Vinante, M. Fiorentino. Surgical Second Look in Ovarian Cancer: A Randomized
Study in patients with laparoscopic Complete Remission-A Northeastern Oncology
Cooperative Group-Ovarian Cancer Cooperative Group Study. J Clin Oncol
15:994-999,1997
8. Nicoletto MO, Padrini R, Koussis H, Rosabian A, Aversa S, Endrizzi L, Azzoni P,
Palumbo M, Fiorentino MV. Continuous mitoxantrone infusion in pretreated
epithelial ovarian cancer. Cancer Chemother Pharmacol. 1995;35(6):506-10.
9. Plebani M, Navaglia F, Basso D, De Paoli M, Nicoletto MO, Maraglino E, Torre
GC. Combined use of urinary UGP and serum CA 125 in the diagnosis of
gynecological cancers. Anticancer Res. 1996 Nov-Dec;16(6B):3833-8.
10. Montagna M., D'Andrea E., Santacaterina M., Menin C., Nicoletto 0. and L.
Chieco-Bianchi. Genetic predisposítion to breast and ovarian cancer. Forum 7.1
(suppl.2) 1997
11. Tasinato R, Godina M, Biral M, Nicoletto O, Griggio L. Peritoneal carcinomatosis
from ovarian cancer: cytoreductive surgery and intraperitoneal chemotherapy. J
Chemother. 1999 Jun;11(3):239-40.
12. MO Nicoletto, C. Mangioni. Tumori. Suppl. 1999
13. Nicoletto M.O., Padrini R., Galeotti F., Ferrazzi E., Cartei G., Palumbo M., De
Paoli M., Corsini A. Pharmacokinetic of hyperthermic intraperitoneal chemotherapy
with mitoxantrone in ovarian
cancer. Cancer Chemother Pharmacol. 2000, 45(6): 457-462.
14. Nicoletto MO, Artioli G, Donach M, Sileni VC, Monfardini S, Talamini R, Veronesi
A, Ferrazzi E, Tumolo S, Visona E, Amichetti M, Endrizzi L, Salvagno L, Prosperi
A, Azzoni P. Elderly ovarian cancer: treatment with mitoxantrone-carboplatin.
Gynecol Oncol. 2001 Feb;80(2):221-6.
15. Menin C, Banna GL, De Salvo G, Lazzarotto V, De Nicolo A, Agata S, Montagna
M, Sordi G, Nicoletto O, Chieco-Bianchi L, D'Andrea E. Lack of association
between androgen receptor CAG polymorphism and familial breast/ovarian
cancer. Cancer Lett. 2001 Jul 10;168(1):31-6.
16. Nicoletto MO, Donach M, De Nicolo A, Artioli G, Banna G, Monfardini S. BRCA-1
and BRCA-2 mutations as prognostic factors in clinical practice and genetic
counselling. Cancer Treat Rev. 2001 Oct;27(5):295-304. Review.
17. Nicoletto O, Donach M, Crivellari G. Polychemotherapy in ovarian cancer in
patients over seventy years of age. Tumori. 2002 Jan-Feb;88(1 Suppl 1):S120-1.
18. ICON (ICON4 centres and consultants) Paclitaxel plus Carboplatin versus
standard chemotherapy with either single-agent carboplatin or
cyclophosphamide,doxorubicin and cisplatin in women with ovarian cancer: the
ICON3 randomised trial.. LANCET 2002; 360:505-15
19. Nicoletto MO, Padrini R, Palumbo M, Ziade A, Ragazzi RS, Pratesi G, Artioli G,
De Cesare M, Zunino F. Intralesional topotecan in advanced ovarian cancer: a
clinical report, based on a preclinical study. Oncol Rep. 2002 Nov-Dec;9(6):13514.
20. ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy
versus conventional platinum-based chemotherapy in women with relapsed
ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet vol 361, June 21, 2003
21. Nicoletto MO, Tumolo S, Falci C, Donach M, Visona E, Rosabian A, Nascimben
O, Cima GP, Vinante O, Azzoni P, Fiorentino MV. A Randomized Study of
Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission? Int
J Med Sci. 2004;1(2):116-125.
22. Agata S, Dalla Palma M, Callegaro M, Scaini MC, Menin C, Ghiotto C, Nicoletto
O, Zavagno G, Chieco-Bianchi L, D'Andrea E, Montagna M. Large genomic
deletions inactivate the BRCA2 gene in breast cancer families. J Med Genet. 2005
Oct;42(10):e64.
23. Venturini M, Bighin C, Monfardini S, Cappuzzo F, Olmeo N, Durando A, Puglisi F,
Nicoletto O, Lambiase A, Del Mastro L. Multicenter phase II study of trastuzumab
in combination with epirubicin and docetaxel as first-line treatment for HER2overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2006
Jan;95(1):45-53.
24. Nicoletto MO, Caltarossa E, Donach M, Nardelli GB, Parenti A, Ambrosini A.
Sertoli cell tumor: a rare case in an elderly patient. Eur J Gynaecol Oncol.
2006;27(1):86-7. Review.
25. Indraccolo S, Tisato V, Agata S, Moserle L, Ferrari S, Callegaro M, Persano L,
Palma MD, Scaini MC, Esposito G, Fassina A, Nicoletto O, Plebani M, Chieco-
Bianchi L, Amadori A, D'Andrea E, Montagna M. Establishment and
characterization of xenografts and cancer cell cultures derived from BRCA1 -/epithelial ovarian cancers. Eur J Cancer. 2006 Jul;42(10):1475-83.
26. Paccagnella A, Oniga F, Bearz A, Favaretto A, Clerici M, Barbieri F, Riccardi A,
Chella A, Tirelli U, Ceresoli G, Tumolo S, Ridolfi R, Biason R, Nicoletto MO,
Belloni P, Veglia F, Ghi MG. Adding gemcitabine to paclitaxel/carboplatin
combination increases survival in advanced non-small-cell lung cancer: results of a
phase II-III study. J Clin Oncol. 2006 Feb 1;24(4):681-7. Erratum in: J Clin Oncol.
2006 May 10;24(14):2220.
27. Nicoletto MO, Falci C, Pianalto D, Artioli G, Azzoni P, De Masi G, Ferrazzi E,
Perin A, Donach M, Zoli W. Phase II study of pegylated liposomal doxorubicin and
oxaliplatin in relapsed advanced ovarian cancer. Gynecol Oncol. 2006
Feb;100(2):318-23.
28. Nicoletto M.O., Donach M., Borgato L., Falci C., Zanin L., De Masi G. Lack of
cardiotoxicity with liposomal doxorubicin in an elderly case of ovarian cancer.
Tumori (2007 Mar-Apr; 93 (2):204-6
29. Nicoletto M.O., Tumolo S., Sorio R., Cima GP., Endrizzi L., Artioli G., Donach M.,
Nascimben O., Vinante O., Azzoni P., Cartei G. Long-term Survival of a
Randomized Study of non-platinum therapy versus platinum in Advanced Epithelial
Ovarian Cancer. Int J Gynecol Can 2007, 17, 986-992
30. Zustovich F, Cartei G, Pastorelli D, Nicoletto O, Gottardo F, De Zorzi L, Dal
Bianco
M.
A phase II study of gemcitabine at fixed infusion rate of 10 mg/m2/min with or
without immunotherapy in advanced renal cancer Anticancer Res. 2007 NovDec;27(6C):4461-4.IF 1.725,
31. Nicoletto M.O.1, Nitti D.2, Pescarini L.3, Corbetti F.4, Mencarelli R.5, Galligioni A.6,
Pogliani C.1, Marchet A.2, Ghiotto C.1, Bozza F.7, Griggio L.8, Zavagno G.2, Donach
M.E.1, Di Maggio C.3 Correlation between Magnetic Resonance Imaging and
Histopathological Tumor Response After Neoadjuvant Chemotherapy in Breast
Cancer. Tumori 94; 481-488, 2008
32. Lhommé C, Joly F, Walker JL, Lissoni A, Nicoletto M.O., Manikas GM,
Baekelandt MO, Gordon AN, Fracasso PM, Mietlowski WL, Jones GJ and Dugan
MH "Phase III Study of Valspodar (PSC 833) Combined With Paclitaxel and
Carboplatin Compared With Paclitaxel and Carboplatin Alone in Patients With
Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary
Peritoneal Cancer" JClin Onco 26,16, june 1 2008, p 2674-2682.
33. M.O.Nicoletto, R.Bertorelle, L.Borgato, G.L.De Salvo, G.Artioli, G. Lombardi, F.
Zustovich, R.Marcato, A.Parenti, M.Montagna, Donach M.E. Family history of
cancer rather than p53 status predicts efficacy of Pegylated Liposomal
Doxorubicin and Oxaliplatin in Relapsed Ovarian Cancer Int J Gynecol Can 2009;
19: 1022-1028
34. G. Artioli, M. Cassaro, L. Pedrini , L. Borgato , L. Corti, A. Cappetta, G. Lombardi,
M.O. Nicoletto . Rare presentation of endometrial carcinoma with singular bone
metastasis. A case report. European Journal of cancer care. Eur J Cancer Care
(Engl). 2009 Jul 29.
35. Lombardi G, Zustovich F, Nicoletto MO, Donach M, Artioli G, Pastorelli D.
Diagnosis and Treatment of Malignant Pleural Effusion: A Systematic Literature
Review and New Approaches. Am J Clin Oncol. 2009 Oct 23.
36. Lombardi G, Zustovich F, Nicoletto MO, Donach M, Pastorelli D. Important Role
of Thiamine in Preventing Ifosfamide-Induced Encephalopathy. J Oncol Pharm
Pract. 2009 Aug 19
37. Lancet Oncol. 2009 Oct;10(10):943-9. Epub 2009 Aug 31. Nadroparin for the
prevention of thromboembolic events in ambulatory patients with metastatic or
locally advanced solid cancer receiving chemotherapy: a randomised, placebocontrolled, double-blind study. Agnelli G, Gussoni G, Bianchini C, Verso M,
Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua
R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M; PROTECHT
Investigators Collaborators (126): Tonato M, Bianchini C, Amadori D, Barbui T,
Cognetti F, Crinò L, Labianca R, Mannucci PM, Moia M, Gianni L, Prandoni P,
Cesana B, de Braud F, Del Favero A, Cavanna L, Lazzaro A, Anselmi E, Mordenti
P, Barni S, Cabiddu M, Petrelli F, Ghilardi M, Labianca R, Poletti P, Marelli B,
Fumagalli D, Buzzi F, Sabatini S, Fumi G, Scambia G, Masi C, Salutari V,
Malaggese M, Passalacqua R, Brighenti M, Lazzarelli S, Donati G, Ricci S, Di
Donato S, Arrighi G, Orlandini C, Gasparini G, Amici S, Verì A, Sarmento R,
Pollera C, Capomolla E, Moschetti L, Garufi C, Campanella C, Torsello A, Misino
A, Lorusso V, Ciuffreda L, Dongiovanni V, Addeo A, Vitale FV, Ferraù F, Priolo D,
Muggiano A, Mulas C, Tedde A, Pogliani EA, Ardizzoia A, Villa F, Montedoro M,
Bravi S, Biagioni F, Palazzo S, Filice A, Crinò L, Gori S, Porrozzi S, Ciccarese M,
Petrucelli L, Chiuri VE, Amadori D, Passardi A, Ravaioli E, Ceravolo R, Crivellari
G, Nicoletto MO, Brandes A, Bertolini S, Benedetti G, Bernardo G, Teragni C,
Jirillo A, Falci C, Santoro A, Masci G, Monti M, Casanova C, Intrivici C, Rinaldi G,
Massidda B, Ionta MT, Dogliotti L, Russo L, Collovà E, Luoni M, Maiello E,
Romano MP, Molica S, Battaglia C, Doni L, Di Costanzo F, Giuliodori L, Silva RR,
Sarobba MG, Pinna A, Sorarù M, Gaion F, Ferrandina G, Gilli G, Locatelli MC,
Zanaboni F, Bologna A, Ferretti G, Chini C, Farina G, Bronner L, Biscottini B,
Tomirotti M, Sciacca V.
38. Nicoletto M. O., M. E. Donach, L. Borgato, F. Angelini, G. Artioli, P. Azzoni, A.
Perin, C. Barile, R. Bertorelle, A. Cecchetto, G. Cartei. Efficacy of pegylated
liposomal doxorubicin (PLD) and oxaliplatin (OX) in pre-treated advanced epithelial
ovarian cancer (EOC) and relation to p53 status. ASCO 2006; Abs. 15054.
39. Lombardi G, Zustovich F, Nicoletto MO, Donach M, Artioli G, Patorelli D.
Diagnosis and treatment of malignant pleural effusion. A systematic literature
review and new approaches. AMERICAN JOURNAL OF CLINICAL ONCOLOGY
2010 aug;33(4):420-3. Review
40. Lombardi G, Zustovich F, Donach M, Dalla Palma M, Nicoletto MO, Pastorelli D
An update on targeted therapy in metastatic renal cell carcinoma UROLOGIC
ONCOLOGY 2010 Apr 22.
41. Lombardi G, Zustovich F, Nicoletto MO, Donach M, Pastorelli D Important role of
thiamine in preventing ifosfamide-induced encephalopathy. J ONCOL PHARM
PRACTICE 2010 Jun 16(2):135-6
42. Pastorelli D, Zustovich F, Faggioni G, Zovato S, Donach M, Nicoletto MO, Farina
M, Furini L, Ceravolo R, Carli P, Lombardi G Good response to second-line
bevacizumab and interferon-a in a sunitinib-refractory patient with metastatic renal
cell carcinoma. ANTI-CANCER DRUGS 2010 Feb; 21(2):210-3.
43. Zustovich F, Lombardi G, Pastorelli D, Farina P, Furini L, Manara R, Dalla Palma
M, Rotilio A, Nicoletto O, Zagonel V. Bevacizumab and glioblastomas, a singlecentre experience: how disease history and characteristics may affect clinical
outcome. Anticancer Res 2010 Dec 30 (12: 5213-6).
44. M. Dalla Palmaa, G. Lombardia, M. E. Donachb, L. Borgatoa, F. Zustovicha, L.
Furinia, M. O. Nicolettoa Tolerability of PLD/Oxaliplatin regimen in recurrent
ovarian cancer patients with previous fragility to carboplatin/paclitaxel treatment .
AM J CLIN ONCOL vol 34, n.3, p.305-8 jun 2011.
45. M. Donach, Y.Yu, G. Artioli, G. Banna, W.Feng, R.C. Bast Jr., Z.Zhang, M.O.
Nicoletto "Combined use of biomarkers for detection of ovarian cancer in high risk
women" TUMOR BIOLOGY, vol.31, N.3, june 2010 p.209-215
46. Lombardi G, Zustovich F, Nicoletto MO, Donach M, Artioli G, Pastorelli D.
Diagnosis and Treatment of Malignant Pleural Effusion: A Systematic Literature
Review and New Approaches. Am J Clin Oncol. 2010 Aug 33 (4) 420-3.
47. M.O. Nicoletto, A. Parenti, P.Del Bianco, G.Lombardi, LL.Pedrini,S.Pizzi, P.Carli,
M. della Palma, D. Pastorelli, L. Corti,L. Beccagli. Vulvar Cancer: Prognostic
Factors. Anticancer Res 30 (6): 2311-7 (2010)
48. Lombardi G, Zustovich F, Nicoletto MO, Donach M, Pastorelli D. Important role of
thiamine in preventing ifosfamide-induced encephalopathy. J Oncol Pharm Pract.
2010 Jun;16(2):135-6.
49. Nicoletto MO, Dalla Palma M, Donach ME, Gusella M, Cappetta A, Shams M,
Marchet A, Nardin M, Pintacuda G, Di Maggio A, Marchesi M, Carli P, Fiduccia P,
Artioli G, Nitti D. Positive experience of intraperitoneal chemotherapy followed by
intravenous chemotherapy in heavily pretreated patients with suboptimal residual
ovarian cancer and primary peritoneal cancer. Tumori. 2010 Nov-Dec;96(6):91825.
50. Zustovich F, Lombardi G, Nicoletto O. Pastorelli D. Second-line therapy for
refractory renal-cell carcinoma. Second-line therapy for refractory renal-cell
carcinoma Crit Rev Oncol Hematol 2011 Sep 21
51. Dalla Palma MD, Lombardi G, Donach ME, Borgato L, Zustovich F, Furini L,
Nicoletto MO. Tolerability of PLD/oxaliplatin regimen in recurrent ovarian cancer
patients with previous fragility to carboplatin/paclitaxel treatment. Am J Clin
Oncol.2011 Jun;34(3):305-8.
52. Safra T, Borgato L, Nicoletto MO, Rolnitzky L, Pelles-Avraham S, Geva R,
Donach ME, Curtin J, Novetsky A, Grenader T, Lai WC, Gabizon A, Boyd L,
Muggia F. BRCA mutation status and determinant of outcome in women with
recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
Mol Cancer Ther. 2011 Oct;10(10):2000-7.
53. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY,
Lambrechts D, Despierre E, Barrowdale D, McGuffog L, Healey S, Easton DF,
Sinilnikova O, Benítez J, García MJ, Neuhausen S, Gail MH, Hartge P, Peock S,
Frost D, Evans DG, Eeles R, Godwin AK, Daly MB, Kwong A, Ma ES, Lázaro C,
Blanco I, Montagna M, D'Andrea E, Nicoletto MO, Johnatty SE, Kjær SK, Jensen
A, Høgdall E, Goode EL, Fridley BL, Loud JT, Greene MH, Mai PL, Chetrit A,
Lubin F, Hirsh-Yechezkel G, Glendon G, Andrulis IL, Toland AE, Senter L, Gore
ME, Gourley C, Michie CO, Song H, Tyrer J, Whittemore AS, McGuire V, Sieh W,
Kristoffersson U, Olsson H, Borg Å, Levine DA, Steele L, Beattie MS, Chan S,
Nussbaum RL, Moysich KB, Gross J, Cass I, Walsh C, Li AJ, Leuchter R, Gordon
O, Garcia-Closas M, Gayther SA, Chanock SJ, Antoniou AC, Pharoah PD;
EMBRACE; kConFab Investigators; Cancer Genome Atlas Research Network.
Association between BRCA1 and BRCA2 mutations and survival in women with
invasive epithelial ovarian cancer. JAMA. 2012 Jan 25;307(4):382-90.
54. Lombardi G, Nicoletto MO, Gusella M, Fiduccia P, Dalla Palma M, Zuin A, Fiore
D, Donach M, Zagonel V. Intrapleural paclitaxel for malignant pleural effusion from
ovarian and breast cancer: a phase II study with pharmacokinetic analysis. Cancer
Chemother Pharmacol. 2012 Mar;69(3):781-7
55. Dalla Palma M, Gregianin M, Fiduccia P, Evangelista L, Cervino AR, Saladini G,
Borgato L, Nicoletto MO, Zagonel V. PET/CT imaging in gynecologic
malignancies: a critical overview of its clinical impact and our retrospective single
center analysis. Crit Rev Oncol Hematol. 2012 Jul;83(1):84-98.
56. Cartei G, Cartei F, Bertin M, Padoan A, Zustovich F, Nicoletto MO, Plebani M.
CA125 reference values change in male and postmenopausal female subjects.
Clin Chem Lab Med. 2012 Sep 25;0(0):1-7.